|
|
|
| Effect of Compound Danshen Dripping Pills combined with Rosuvastatin on left ventricular remodeling and myocardial fibrosis in patients with acute myocardial infarction after percutaneous coronary intervention |
| XU Xiaojin ZHANG Yiyan ZHANG Sujie GONG Juexiao LOU Bin GU Minglin YU Shengyong |
| Department of Cardiovascular, Jiangsu Province Academy of Traditional Chinese Medicine, Jiangsu Province, Nanjing 210028, China |
|
|
|
Abstract Objective To investigate the effects of Compound Danshen Dripping Pills combined with Rosuvastatin on left ventricular remodeling (LVR) and myocardial fibrosis in patients with acute myocardial infarction (AMI) after percutaneous coronary intervention (PCI). Methods Eighty patients with AMI who underwent PCI surgery in Jiangsu Province Academy of Traditional Chinese Medicine from January 2015 to June 2018 were selected and divided into observation group and control group according to the random number table method, with 40 cases in each group. Both groups were given routine treatment after operation, and control group was treated with Rosuvastatin, while observation group was treated with Compound Danshen Dripping Pills on the basis of control group. Clinical effect, traditional Chinese medical syndrome score, echocardiography index, laboratory index before and after treatment and adverse drug reactions were compared between two groups. Results Total clinical effective rate of observation group was higher than that of control group (P < 0.05). After treatment, traditional Chinese medical syndrome scores of two groups were significantly lower than those before treatment, and observation group was lower than control group (P < 0.05). After treatment, left ventricular ejection fraction of two groups was significantly higher than that before treatment, and observation group was higher than control group (P < 0.05). After treatment, left ventricular end diastolic dimension and left ventricular end systolic diameter in two groups were significantly smaller than those before treatment, and observation group was smaller than control group (P < 0.05). After treatment, levels of matrix metalloproteinases-9, transforming growth factor-β1 and connective tissue growth factor in two groups were lower than those before treatment, and observation group was lower than control group (P < 0.05). During the treatment, there was no obvious adverse reaction in both groups. Conclusion The combination of Rosuvastatin and Compound Danshen Dripping Pills can effectively improve the clinical symptoms of AMI patients after PCI, and delay the progression of LVR and myocardial fibrosis.
|
|
|
|
|
|
| Cite this article: |
|
XU Xiaojin ZHANG Yiyan ZHANG Sujie GONG Juexiao LOU Bin GU Minglin YU Shengyong. Effect of Compound Danshen Dripping Pills combined with Rosuvastatin on left ventricular remodeling and myocardial fibrosis in patients with acute myocardial infarction after percutaneous coronary intervention[J]. 中国医药导报, 2019, 16(35): 61-64,77.
|
|
|
|
| URL: |
| http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2019/V16/I35/61 |
[1] 金杰，曾光豪，潘慧.PCI救治老年急性心肌梗死患者的疗效及近期预后影响因素分析[J].医学临床研究，2017， 34（8）：1561-1564.
[2] 李兆欣，刘江月，李静静，等.不同剂量瑞舒伐他汀治疗对急性心肌梗死患者心肌纤维化及心室重构的影响[J].中国循证心血管医学杂志，2016，8（1）：46-50.
[3] 郭文玉，彭长农，柯晓，等.冠状动脉微循环障碍加速大鼠心肌梗死后不良心室重构的机制研究[J].新医学，2017，48（48）：848.
[4] 安杰，温盛燕，佘强，等.负荷他汀类药物对急性ST段抬高型心肌梗死患者介入治疗术后疗效的Meta分析[J].第三军医大学学报，2017，39（23）：2316-2322.
[5] 马世堂，戴国梁，程小桂，等.基于系统虚拟药理学复方丹参滴丸抗血小板聚集药效物质基础研究[J].中药材，2018，41（1）：189-194.
[6] 中华医学会心血管病学分会，中华心血管病杂志编辑委员会，《中国循环杂志》编辑委员会，等.急性心肌梗死诊断和治疗指南[J].中华心血管病杂志，2001，29（12）：710-725.
[7] 中华医学会心血管病学分会介入心脏病学组，中华心血管病杂志编辑委员会.中国经皮冠状动脉介入治疗指南2012（简本）[J].中华心血管病杂志，2012，40（4）：271-277.
[8] 国家中医药管理局医政司胸痹急症协作组东北分组.胸痹心厥（冠心病心肌梗塞）急症诊疗规范[J].中国中医急症，1995，4（4）：183-185.
[9] 王岱岱，姚震，钟江华，等.急性心肌梗死患者Killip心功能分级与血浆促心肌素-1浓度变化的关系[J].岭南心血管病杂志，2009，15（5）：354-356，362.
[10] 郑筱萸.中药新药临床研究指导原则（试行）[M].北京：中国医药科技出版社，2002：68-85.
[11] 黄凤荣，苟志平，徐珊.大剂量瑞舒伐他汀对急性心肌梗死后心肌纤维化、心室重构及心功能的影响[J].海南医学，2017，28（3）：369-371.
[12] 史云娟，何国平.不同剂量瑞舒伐他汀治疗急性心肌梗死后再灌注损伤的疗效及安全性[J].中国医院用药评价与分析，2017，17（9）：1188-1190.
[13] 张晶晶，杨瑞.疏血通注射液对急性心肌梗死患者的疗效及对微循环及血小板状态的影响研究[J].世界中医药，2017，12（7）：1540-1543.
[14] 石斌豪，徐宗佩，樊官伟.基于TGF-β1/Smads信号通路治疗心肌梗死后心肌纤维化的研究进展[J].中国药理学通报，2018，34（1）：5-8.
[15] 洪涛.欧洲心脏病学会2017版急性ST段抬高型心肌梗死诊断和治疗指南更新之我见[J].中国介入心脏病学杂志，2017，25（9）：483-485.
[16] 沈豪，郭霜，刘秀芬，等.TGF-β/Smads信号通路在姜黄素改善糖尿病大鼠心肌纤维化中的作用[J].中国药理学通报，2018，34（4）：522-527.
[17] 宋惠霄，刘艳红，陈鲁，等.童心康合剂对实验性自身免疫性心肌炎大鼠心肌纤维化的影响[J].中国医院药学杂志，2018，38（6）：610-614.
[18] 周松，黄玲芳，李振莲，等.通心络胶囊联合西药治疗急性心肌梗死患者的疗效及对炎性因子的影响[J].世界中医药，2018，13（1）：88-90，94.
[19] 邵建兵，汪燕，王加林，等.麝香保心丸治疗冠心病急性心肌梗死44例[J].西部中医药，2017，30（12）：61-64.
[20] 王镇.瑞舒伐他汀不同给药剂量对急性心肌梗死患者心肌纤维化及心室重构的影响研究[J].临床医学，2017（1）：65-67.
[21] 常虹，李正国，杨庆国，等.复方丹参滴丸药理作用及代谢研究进展[J].中国药物警戒，2016，13（11）：682-685.
[22] 管铮，陈玉红，邓振兴，等.复方丹参滴丸治疗冠心病心绞痛的临床研究[J].中国现代医生，2017，55（11）：97-99.
[23] 王宇彤，李莉.益气活血通络法治疗急性心肌梗死介入术后患者43例[J].西部中医药，2017，30（6）：68-71.
[24] 刘灿，海宝，张稳，等.骨内单次注射小剂量辛伐他汀对大鼠心梗后血管新生的影响[J].中国实验动物学报，2017， 25（5）：506-512.
[25] 谢亚芹，赵娟，康大伟，等.不同剂量瑞舒伐他汀对急性心肌梗死大鼠心肌纤维化的影响及机制[J].广东医学，2018，39（2）：195-198.
[26] 戢艳琼，李梓香，左金梅.经皮冠状动脉介入术后应用复方丹参滴丸辅助治疗急性心肌梗死的疗效观察[J].内科急危重症杂志，2019，25（3）：243-245.
[27] 孔宏亮，苗志林，郭翠艳，等.人参皂苷Rbl对阿霉素心力衰竭大鼠心肌细胞核因子-κB的影响[J].中国药理学通报，2013，29（4）：573-576.
[28] 张怡，王勇，孟慧，等.复方丹参片调控AT1介导花生四烯酸PLA2-COX2/5-LOX代谢途径防治心力衰竭的机制研究[J].中国中药杂志，2018，43（12）：2593-2599. |
|
|
|
